31 May 2021 – Dr. Wild & Co. AG, the well-known Swiss family-owned company will focus on its Oral Care business in the future and, therefore, sold its Pharma business (OTX/OTC), incl. its product portfolio in Vitamin D and other well-known products such as, for example, Oxyplastin, Deaftol, Contra-Schmerz, Tonoglutal and Salvia Wild to Verfora AG. Verfora is part of the listed Galenica Group (SIX Swiss Exchange: GALE).

Walder Wyss advised Dr. Wild & Co. AG in this transaction. The team was led by Robert von Rosen (Partner, Corporate/M&A) and further included Andreas Wildi (Partner, Life Sciences), Pandora Kunz-Notter (Managing Associate, Regulatory), Michelle Bruni (Senior Associate, Tax), Michael Schmassmann (Associate, Competition) and Luca A. Sprecher (Trainee, Corporate/M&A).